secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axogen, Inc. (AXGN)
CIK:        0000805928
Form:       8-K
Filed at:   2025-12-04T23:59:59+00:00
Accession:  0000805928-25-000140
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axogen receives FDA approval of BLA for Avance nerve allograft under Accelerated Approval pathway
--------------------------------------------------------------------------------

- FDA approved Biologics License Application for Avance (acellular nerve allograft) for sensory, mixed, motor nerve discontinuities in adults and pediatric patients 1 month+.
- Indications for sensory gaps >25mm and mixed/motor gaps approved under Accelerated Approval pathway; continued approval depends on confirmatory studies.
- Commercial launch of licensed Avance expected early Q2 2026; product remains available under current tissue framework until then.
- CEO Michael Dale says approval strengthens regulatory footing and confirms Avance as safe, pure, potent therapeutic option.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/805928/000080592825000140/0000805928-25-000140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/805928/000080592825000140/axgn-20251203.htm
  HTML page:      https://secwatch.observer/filing/0000805928-25-000140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer